BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1-positive patients.

与 PD-1/PD-l1 阻断相比，CTLA-4 和 PD-1/PD-l1 双重阻断，并未显著改善复发/转移性宫颈癌（R/M CC）患者的临床结局。 本研究通过多 ...

A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from the electronic health ...

经济观察网讯 2月21日，中国国家药监局药品审评中心（CDE）官网最新公示，阿斯利康（AstraZeneca）的抗PD-L1单抗度伐利尤单抗注射液又一项新适应症 ...

The PD-L1 expression is determined by the LifeTracDx ® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...

such as PD-1/PD-L1 inhibitors and CAR-T technology. However, the industry is constantly looking to discover the next frontier in treatment development and technology to provide more effective ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma.

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the ...

With this acquisition, Sun Pharma strengthens its oncology portfolio by integrating UNLOXCYT, the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous ...